Salomon & Ludwin’s Catalyst Pharmaceutical CPRX Stock Holding History

Salomon & Ludwin’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1,942	Closed	-$61.1K	–	1723
2026 Q2	$61.1K	Buy	1,942 +76	+4%	+$2.24K	0.01%	457
2026 Q1	$46.1K	Buy	1,866 +1,093	+141%	+$26K	﹤0.01%	523
2025 Q4	$17.6K	Sell	773 -175	-18%	-$3.9K	﹤0.01%	1002
2025 Q3	$19.8K	Buy	+948	New	+$19.5K	﹤0.01%	824

Other funds holding CPRX

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Salomon & Ludwin's CPRX Position: Q3 2026 in Review

Salomon & Ludwin sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 1,942 shares — an estimated $61.1K sold.

Salomon & Ludwin first reported a position in CPRX in Q3 2025 and held it in 4 quarters. The position peaked at $61.1K in Q2 2026. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

Salomon & Ludwin reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
Salomon & Ludwin sold 1,942 Catalyst Pharmaceutical shares in Q3 2026, an estimated $61.1K.
Salomon & Ludwin first reported a position in Catalyst Pharmaceutical in Q3 2025 and held it in 4 quarters.
Salomon & Ludwin's Catalyst Pharmaceutical position peaked at $61.1K in Q2 2026.
2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Salomon & Ludwin's 13F filing for Q3 2026, filed 29 Oct 2026.